About Probable tubulin polyglutamylase TTLL2
Probable tubulin polyglutamylase TTLL2 (TTLL2) is a protein
from Homo sapiens identified by UniProt accession
Q9BWV7, 592 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Probable tubulin polyglutamylase TTLL2 |
| UniProt accession | Q9BWV7 |
| Gene | TTLL2 |
| Organism | Homo sapiens |
| Length | 592 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (6)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.17
- urinary metabolite measurement · score 0.08
- mean corpuscular volume · score 0.03
- small cell lung carcinoma · score 0.01
- cancer · score 0.00
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BWV7-F1 | alphafold | PREDICTED | 71.34 | — |
Amino-acid sequence (592 residues)
MRGRDLCSST QSQALGSLRT TTPAFTLNIP SEANHTEQPP AGLGARLQEA GVSIPPRRGR PTPTLEKKKK PHLMAEDEPS GALLKPLVFR VDETTPAVVQ SVLLERGWNK FDKQEQNAED WNLYWRTSSF RMTEHNSVKP WQQLNHHPGT TKLTRKDCLA KHLKHMRRMY GTSLYQFIPL TFVMPNDYTK FVAEYFQERQ MLGTKHSYWI CKPAELSRGR GILIFSDFKD FIFDDMYIVQ KYISNPLLIG RYKCDLRIYV CVTGFKPLTI YVYQEGLVRF ATEKFDLSNL QNNYAHLTNS SINKSGASYE KIKEVIGHGC KWTLSRFFSY LRSWDVDDLL LWKKIHRMVI LTILAIAPSV PFAANCFELF GFDILIDDNL KPWLLEVNYS PALTLDCSTD VLVKRKLVHD IIDLIYLNGL RNEGREASNA THGNSNIDAA KSDRGGLDAP DCLPYDSLSF TSRMYNEDDS VVEKAVSVRP EAAPASQLEG EMSGQDFHLS TREMPQSKPK LRSRHTPHKT LMPYASLFQS HSCKTKTSPC VLSDRGKAPD PQAGNFVLVF PFNEATLGAS RNGLNVKRII QELQKLMNKQ HS
Explore Probable tubulin polyglutamylase TTLL2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets